Aug. 22 Clinical Quick Takes: Rituximab biosimilar meets endpoint; plus Aimmune, NKMax, Calibr

Rituximab biosimilar meets NHL endpoint
Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said top-line results from the Phase III JASMINE study showed rituximab biosimilar (ABP 798) met the trial's primary endpoint of clinical equivalence to Rituxan rituximab in CD20-positive non-Hodgkin lymphoma patients. The anti-CD20 mAb led to an overall response rate within the prespecified margin at week 28 vs. Rituxan, with similar safety and immunogenicity. In January, the partners announced positive top-line data showing Rituxan equivalence for the biosimilar in rheumatoid arthritis.

Aimmune starts Phase II egg allergy study
Aimmune Therapeutics Inc. (NASDAQ:AIMT) said it enrolled the first patient in a Phase II trial of AR201 for egg allergy. The oral immunotherapy comprises dried egg white protein delivered using the company's characterized oral desensitization immunotherapy (CODIT) system...